Clinical Trial Update: Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study of AVE0010, a GLP-1 receptor agonist, in metformin-treated adults with Type 2 Diabetes Mellitus has completed. The report summarizes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AVE0010

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes | Phase 2 | Status: COMPLETED